{
    "paper_id": "PMC6797864",
    "metadata": {
        "title": "The role of CCR1 and therapeutic effects of anti\u2010CCL3 antibody in herpes simplex virus\u2010induced Beh\u00e7et's disease mouse model",
        "authors": [
            {
                "first": "Hasan",
                "middle": [
                    "M."
                ],
                "last": "Sayeed",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Eun\u2010So",
                "middle": [],
                "last": "Lee",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Hae\u2010Ok",
                "middle": [],
                "last": "Byun",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Seonghyang",
                "middle": [],
                "last": "Sohn",
                "suffix": "",
                "email": "sohnsh@ajou.ac.kr",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Beh\u00e7et's disease (BD) is a chronic systemic inflammatory disease with unclear etiopathogenesis. Gene variants of CC chemokine receptor type 1 (CCR1) in patients with BD have been identified by genome\u2010wide association studies.1, 2 However, the CCR1 protein expression in patients with BD or in mouse models remains unclear.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "CC chemokine receptor type 1 is expressed in cells of the immune system, including lymphocytes, monocytes, neutrophils and dendritic cells.3, 4 It is involved in host defense, hematopoiesis, T helper type 1/2 (Th1/2) cell balance, and chemotaxis.5, 6 The CCR1 expression is correlated with various inflammatory diseases, including rheumatoid arthritis,7 asthma8 and lupus nephritis.9 CCR1 knockout (\u2212/\u2212) mice show reduced pulmonary inflammation,10 and prolonged allograft survival.11 CCR1 polymorphism might be a general risk factor for autoimmune or inflammatory disease. CCR1 antagonists have been used in clinical trials to treat multiple sclerosis, psoriasis and rheumatoid arthritis.12\n",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Herpes simplex virus (HSV) has been reported as an etiological factor in BD.13, 14, 15 A mouse model of HSV\u2010induced inflammatory BD was developed and used in various studies.16, 17, 18, 19 The objective of the present study was to determine the expression of CCR1 in mice with inflammatory BD symptoms and to investigate whether CCR1 was regulated by ligands, agonists or antagonists. Flow cytometry was used to examine the frequencies of CCR1+ cells on the surface and in the cytoplasm of lymph node (LN) cells and peripheral blood mononuclear cells (PBMC). Our results demonstrated the correlation between CCR1 surface expression on PBMC and the severity of BD symptoms in mice.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Male ICR mice (4 weeks old) were infected with HSV type 1 (1 \u00d7 106 plaque\u2010forming units/ml, F strain) grown in Vero cells as described previously.16 The virus was inoculated twice into mice at a frequency of 10 days. After the second HSV inoculation, mice were observed from week 4 to week 32. Animals were handled in accordance with guidelines provided by the Institutional Animal Care and Use Committee of Ajou University School of Medicine (AMC\u20102016\u20100010).",
            "cite_spans": [],
            "section": "Animal experiments ::: Animal experiments ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Among all the mice infected with HSV, 15% developed BD\u2010like symptoms including skin ulcerations, skin pustules, genital ulcerations, erythema, oral ulceration, ear inflammation, arthritis, genital ulcerations, red eye (left, right), reduced vision (left, right), weight loss and facial swelling. Oral, genital and skin ulcers, and eye symptoms were classified as major symptoms. Other symptoms were identified as minor symptoms. Mice displaying more than one major and one minor symptom were diagnosed with BD. Each symptom score was assigned a single point. The sum of all symptom scores was used to determine the severity of BD. Disappearance of symptoms or \u226520% decrease in lesion size was classified as symptom improvement. The disease severity score of BD was calculated according to the BD activity index outlined in the BD Activity Form ( www.behcet.ws/pdf/BehcetsDiseaseActivityForm.pdf). HSV\u2010inoculated, but asymptomatic, healthy mice (BDN mice) served as the control group, as described previously.",
            "cite_spans": [],
            "section": "Symptoms of BD in mice ::: Animal experiments ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Peripheral blood mononuclear cells and LN cells were isolated from mice. Erythrocytes were eliminated with ammonium\u2013chloride\u2013potassium solution and washed with phosphate\u2010buffered saline (PBS) followed by surface staining of 1 \u00d7 106 cells with mouse CCR1 allophycocyanin\u2010conjugated antibody (cat# FAB5986A; R&D Systems, Minneapolis, MN) for 30 min at 4\u00b0 in the dark. For intracytoplasmic staining, cells were fixed in intracytoplasmic fixation buffer for 20 min at room temperature. After washing twice with a permeabilization buffer, 1 \u00d7 106 cells were stained with an anti\u2010mouse CCR1 antibody, followed by analysis of these cells with a flow cytometer (FACS Canto II; Becton Dickinson, San Jose, CA).",
            "cite_spans": [],
            "section": "Flow cytometry ::: Animal experiments ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Fresh PBMC were washed twice with cold PBS and lyzed with lysis buffer (50 mm Tris\u2013Cl, pH 7\u00b74, 0\u00b715 m NaCl, 1 mm EDTA, 1% Triton X\u2010100, 10 \u03bcg/ml each of aprotinin and leupeptin, and 1 mm phenylmethylsulphonyl fluoride). The protein (30 \u03bcg) lysate was electrophoresed on a 10% sodium dodecyl sulfate\u2013polyacrylamide gel. The proteins were transferred onto nitrocellulose membranes (Protran; GE Healthcare Life Sciences, Chicago, IL, USA) and subjected to immunoblot analysis using antibodies. The immunoblots were developed with the enhanced chemiluminescence system (GE Healthcare Life Sciences). Antibody against CCR1 (MAB5986) was purchased from R&D Systems and glyceraldehyde 3\u2010phosphate dehydrogenase (GAPDH) antibody (sc\u201032233) was from Santa Cruz Biotechnology, Inc. (Dallas, TX).",
            "cite_spans": [],
            "section": "Western blot analysis ::: Animal experiments ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Normal and BD mice were treated in vivo with PBS, interleukin\u201010 (IL\u201010) (50 pg/mouse/day) (cat# CYT\u2010497; Prospecbio, Ness\u2010Ziona, Israel), granulocyte\u2013macrophage colony\u2010stimulating factor (GM\u2010CSF) (200 pg/mouse/day) (cat# CYT\u2010222; Prospecbio), chemokine CC motif ligand 3 (CCL3) (100 pg/mouse/day) (cat# CHM\u2010320; Prospecbio), or anti\u2010CCL3 antibody (20 ng/mouse/day) (cat# AF\u2010450\u2010NA; R&D Systems) for five consecutive days by intraperitoneal administration. Normal mice were 3\u00b75 weeks old. PBMC and LN cells were isolated 3 hr after the last medication for analysis of CCR1+ cells by flow cytometry. BX471, a CCR1 antagonist (cat# SML0020; Sigma\u2010Aldrich, St Louis, MO), was intraperitoneally administered to normal and BD mice at 0\u00b75 mg/mouse three times (every other day). BD symptoms were observed before and after treatment. Images were obtained to document the treatment\u2010related changes.",
            "cite_spans": [],
            "section": "Administration of cytokines, ligand and antagonist ::: Animal experiments ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Mice were treated orally with PBS, colchicine (2 \u03bcg/mouse/day), or pentoxifylline (400 \u03bcg/mouse/day) for five consecutive days. Changes in symptoms were monitored. At 3 hr after the last medication, the mice were killed by intramuscular injection into the hind leg with a ketamine/xylazine cocktail (15 mg/kg ketamine and 10 mg/kg xylazine). PBMC and LN cells were isolated for analysis of CCR1+ cells.",
            "cite_spans": [],
            "section": "Drug treatments ::: Animal experiments ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "The patient population consisted of 12 patients with BD, who presented for the first time or were monitored at the Department of Dermatology, Ajou University Hospital. Sampling from patients with BD was random when the patients first arrived. Clinical characteristics and therapeutic histories of these patients are shown in Tables 1 and 2. According to the International Study Group for BD criteria, the presence of any two of the following symptoms, in addition to recurrent oral ulcerations, is considered as BD diagnosis: recurrent genital ulceration, cutaneous erythema nodosum, large\u2010vessel vasculitis, arthritis, uveitis, and/or a positive pathergy test. The disease severity score was calculated from Beh\u00e7et's disease current activity form 2006 (http://www.behcetdiseasesociety.org/behcetwsData/Uploads/files/BehcetsDiseaseActivityForm.pdf). Patients with active BD (n = 12, 11 men, one woman, 45\u00b70 \u00b1 10\u00b72 years) were enrolled. Gender differences among BD patients with mucocutaneous manifestations were inconsistent among different nationalities.20 Informed consent was obtained from patients before the study. The healthy control group (n = 12, 48\u00b78 \u00b1 9\u00b72 years) comprised one man and 11 women. Serum was provided by the Biobank of Ajou University Hospital, a member of the Korea Biobank Network. This study was approved by the ethics committee of Ajou University Medical Center Institutional Review Board (AJIRB\u2010GN3\u201007\u2010098) and all experiments were conducted according to the Institutional Review Board permitted protocol.",
            "cite_spans": [],
            "section": "Patients with BD ::: Animal experiments ::: Materials and methods",
            "ref_spans": [
                {
                    "start": 332,
                    "end": 333,
                    "mention": "1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 338,
                    "end": 339,
                    "mention": "2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "Peripheral blood was collected in EDTA\u2010coated test tubes and centrifuged at 1000 g for 5 min at 20\u00b0. The supernatant was stored at \u221270\u00b0 until used. CCL3 levels were measured in plasma using a commercial enzyme\u2010linked immunosorbent assay (ELISA) kit (Cat# BMS2029INST; Thermo Fisher Scientific, Waltham, MA) following the manufacturer's instructions. For ELISA analysis, each sample was applied in duplicate wells and three times in different ELISA plates.",
            "cite_spans": [],
            "section": "CCL3 ELISA ::: Animal experiments ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "The data and statistical analysis complied with the recommendations of experimental design and analysis in pharmacology.",
            "cite_spans": [],
            "section": "Statistical analysis ::: Animal experiments ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Flow cytometric analysis was performed to analyze the surface and cytoplasm CCR1+ cells stained with anti\u2010CCR1 antibody for PBMC and LN cells isolated from normal (n = 10), BDN (n = 10), and BD (n = 10) mice. Frequencies of CCR1+ cells on the surface of PBMC were significantly down\u2010regulated in BD mice compared with those in normal mice (7\u00b706 \u00b1 1\u00b78% versus 11\u00b711 \u00b1 2\u00b75%, P = 0\u00b70005) or BDN mice (7\u00b706 \u00b1 1\u00b78% versus 10\u00b758 \u00b1 1\u00b792%, P = 0\u00b70006). Frequencies of CCR1+ cells on the surface of LN cells were also down\u2010regulated in BD mice compared with normal mice (10\u00b76 \u00b1 3\u00b72% versus 12\u00b799 \u00b1 1\u00b75%, P = 0\u00b705) or BDN mice (10\u00b76 \u00b1 3\u00b72% versus 11\u00b712 \u00b1 2\u00b71%, P = 0\u00b767) (Fig. 1a).",
            "cite_spans": [],
            "section": "Frequencies of CCR1+ cells in BD mice ::: Results",
            "ref_spans": [
                {
                    "start": 667,
                    "end": 668,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                }
            ]
        },
        {
            "text": "The frequencies of cytoplasm staining in CCR1+ PBMC were significantly lower in BD mice than in normal mice (32\u00b708 \u00b1 16\u00b73% versus 73\u00b76 \u00b1 3%, P < 0\u00b70001) or BDN mice (32\u00b708 \u00b1 16\u00b73% versus 58\u00b74 \u00b1 11\u00b705%, P = 0\u00b70005). The frequencies of CCR1+ LN cells were also significantly lower in BD mice than in normal mice (58\u00b704 \u00b1 22\u00b739% versus 82\u00b714 \u00b1 8\u00b715%, P = 0\u00b7005). There were no differences in frequencies of CCR1+ cells between BD and BDN mice (58\u00b704 \u00b1 22\u00b739% versus 59\u00b710 \u00b1 27\u00b76, P = 0\u00b79) (Fig. 1b). Representative histograms of surface staining results are presented in Fig. 1(c). Figure 1(d) shows the Western blot analysis for CCR1 expression in whole PBMC lysates in normal, BDN and BD mice (n = 3 in each group). The expression ratio of CCR1 compared with GAPDH was not different between BDN (1\u00b742 \u00b1 0\u00b734) and BD (1\u00b748 \u00b1 1\u00b715) mice (Fig. 1e, n = 7). This means the entire amount of CCR1 in PBMC was not correlated with the symptoms.",
            "cite_spans": [],
            "section": "Frequencies of CCR1+ cells in BD mice ::: Results",
            "ref_spans": [
                {
                    "start": 492,
                    "end": 493,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 573,
                    "end": 574,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 586,
                    "end": 587,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 840,
                    "end": 841,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                }
            ]
        },
        {
            "text": "Interleukin\u201010 synergistically enhanced GM\u2010CSF\u2010induced CCR1.21 GM\u2010CSF is known as a CCR1\u2010enhancing cytokine.22 Therefore, IL\u201010 and GM\u2010CSF were administered to normal and BD mice. To determine the functional doses in mice in vivo, IL\u201010 and GM\u2010CSF were injected into 3\u00b75\u2010week\u2010old normal mice intraperitoneally at the following doses: IL\u201010 (25, 50 and 100 pg) and GM\u2010CSF (50, 100 and 200 pg). At 3 hr after the last treatment, PBMC were isolated from mice for flow cytometry to measure the frequencies of CCR1+ cells on the surface and cytoplasm.",
            "cite_spans": [],
            "section": "Interleukin\u201010 and GM\u2010CSF affect frequencies of CCR1+ cells in normal mice ::: Results",
            "ref_spans": []
        },
        {
            "text": "In mice treated with 50 pg of IL\u201010 (n = 13), the frequencies of surface CCR1+ cells were significantly up\u2010regulated in PBMC compared with PBS\u2010treated control mice (n = 5) (13\u00b714 \u00b1 0\u00b79% versus 11\u00b70 \u00b1 0\u00b73%, P = 0\u00b7009). Treatment with 25 pg of IL\u201010 (n = 9) did not affect the frequencies of CCR1+ cells compared with PBS\u2010treated control mice (n = 5) (11\u00b774 \u00b1 0\u00b796% versus 11\u00b70 \u00b1 0\u00b73%, P = 0\u00b747). Treatment with 100 pg of IL\u201010 (n = 6) up\u2010regulated the frequencies of CCR1+ cells compared with PBS\u2010treated control mice (n = 5), although the difference was not statistically significant (13\u00b765 \u00b1 2\u00b705% versus 11\u00b70 \u00b1 0\u00b73%, P = 0\u00b718). The frequencies of cytoplasm CCR1+ PBMC were slightly increased in mice treated with 50 pg of IL\u201010 and 100 pg of IL\u201010 compared with those in PBS\u2010treated control mice (62\u00b7575 \u00b1 9\u00b789% versus 56\u00b705 \u00b1 23\u00b712%, P = 0\u00b76; 58\u00b78 \u00b1 23\u00b733% versus 56\u00b705 \u00b1 23\u00b712%, P = 0\u00b79), although the differences were not statistically significant (Fig. 2a).",
            "cite_spans": [],
            "section": "Interleukin\u201010 and GM\u2010CSF affect frequencies of CCR1+ cells in normal mice ::: Results",
            "ref_spans": [
                {
                    "start": 959,
                    "end": 960,
                    "mention": "2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "In normal mice exposed to 200 pg of GM\u2010CSF (n = 5), the frequencies of surface CCR1+ PBMC were up\u2010regulated compared with PBS\u2010treated control mice (15\u00b765 \u00b1 1\u00b74% versus 11\u00b70 \u00b1 0\u00b742%, P = 0\u00b705). In mice treated with 100 pg of GM\u2010CSF (n = 6), the frequencies of CCR1+ cells were higher compared with the levels in PBS\u2010treated control mice (n = 5) (13\u00b775 \u00b1 1\u00b734% versus 11\u00b70 \u00b1 0\u00b73%, P = 0\u00b711). However, the difference was not statistically significant. Mice treated with 50 pg of GM\u2010CSF (n = 6) showed frequencies of CCR1+ cells similar to those in PBS\u2010treated control mice (n = 5). In the cytoplasm of PBMC, frequencies of CCR1+ cells in mice treated with GM\u2010CSF at 50, 100 and 200 pg (62\u00b725 \u00b1 3\u00b718%; 63\u00b795 \u00b1 1\u00b79%; 64\u00b77 \u00b1 1\u00b75%, respectively) were not significantly (P > 0\u00b705) different compared with those in the PBS control group (56\u00b705 \u00b1 23\u00b712%) (Fig. 2b).",
            "cite_spans": [],
            "section": "Interleukin\u201010 and GM\u2010CSF affect frequencies of CCR1+ cells in normal mice ::: Results",
            "ref_spans": [
                {
                    "start": 851,
                    "end": 852,
                    "mention": "2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "According to functional doses of IL\u201010 and GM\u2010CSF in normal mice, 50 pg/mouse/day of IL\u201010 and 200 pg/mouse/day of GM\u2010CSF were administered to BD mice to up\u2010regulate CCR1+ cells. After five consecutive days of treatment to BD mice, PBMC and LN cells were subjected to surface and cytoplasm staining for FACS analysis. In the surface of PBMC, the frequencies of CCR1+ cells in BD mice treated with IL\u201010 (n = 7) and GM\u2010CSF (n = 7) showed significant up\u2010regulation compared with those in PBS\u2010treated BD mice (n = 10) (IL\u201010 versus PBS: 13\u00b761 \u00b1 2\u00b75% versus 7\u00b706 \u00b1 1\u00b78%, P < 0\u00b70001; GM\u2010CSF versus PBS: 9\u00b70 \u00b1 1\u00b73% versus 7\u00b706 \u00b1 1\u00b78%, P = 0\u00b703). The surface CCR1+ LN cells were significantly up\u2010regulated compared with PBS\u2010treated BD mice (IL\u201010 versus PBS: 17\u00b76 \u00b1 2\u00b77% versus 10\u00b76 \u00b1 3\u00b723%, P = 0\u00b70002; GM\u2010CSF versus PBS: 15\u00b74 \u00b1 1\u00b76% versus 10\u00b76 \u00b1 3\u00b723%, P = 0\u00b7003) (Fig. 2c). In the cytoplasm, CCR1+ PBMC also increased after treatment with IL\u201010 (54\u00b767 \u00b1 5\u00b700% versus 32\u00b704 \u00b1 16\u00b73%, P = 0\u00b702) and GM\u2010CSF (82\u00b71 \u00b1 6\u00b74% versus 32\u00b708 \u00b1 16\u00b73%, P = 0\u00b7001) compared with PBS\u2010treated BD mice. Cytoplasm CCR1+ cells in LN were increased only by GM\u2010CSF (77\u00b785 \u00b1 5\u00b79% versus 58\u00b704%, P = 0\u00b704). Frequencies of cytoplasm CCR1+ LN cells were not changed after IL\u201010 treatment (Fig. 2d). IL\u201010 and GM\u2010CSF up\u2010regulated the frequencies of CCR1+ cells in both normal and BD mice.",
            "cite_spans": [],
            "section": "Interleukin\u201010 and GM\u2010CSF up\u2010regulate frequencies of CCR1+ cells in BD mice ::: Results",
            "ref_spans": [
                {
                    "start": 866,
                    "end": 867,
                    "mention": "2",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 1264,
                    "end": 1265,
                    "mention": "2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "CCR1 has multiple ligands. CCL3 is one of its ligands for CCR1 down\u2010regulation function.23 To determine whether CCR1 was regulated by CCL3, CCL3 was intraperitoneally injected into normal mice. Frequencies of CCR1+ PBMC and LN cells were decreased after CCL3 treatment. In surface staining of PBMC, treatment with 100 pg of CCL3 (n = 6) significantly decreased the frequencies of CCR1+ cells compared with PBS control (n = 5) (4\u00b762 \u00b1 1\u00b73% versus 12\u00b792 \u00b1 1\u00b789%, P = 0\u00b70002). Treatment with 50 pg CCL3 decreased frequencies of CCR1+ cells, although the decrease was not significant (9\u00b705 \u00b1 2\u00b77% versus 12\u00b792 \u00b1 1\u00b789%, P = 0\u00b706). In surface staining of LN cells, treatment with CCL3 at 100 pg (n = 6) significantly down\u2010regulated the frequencies of CCR1+ cells compared with PBS control (n = 5) (9\u00b742 \u00b1 1\u00b732% versus 13\u00b715 \u00b1 1\u00b77%, P = 0\u00b7009). Treatment with CCL3 50 pg (n = 6) resulted in similar frequencies of CCR1+ cells compared with PBS\u2010treated control mice (Fig. 3a).",
            "cite_spans": [],
            "section": "CCL3 down\u2010regulates the expression of CCR1+ cells in normal mice ::: Results",
            "ref_spans": [
                {
                    "start": 964,
                    "end": 965,
                    "mention": "3",
                    "ref_id": "FIGREF2"
                }
            ]
        },
        {
            "text": "The frequencies of cytoplasm CCR1+ PBMC after treatment with CCL3 at 50 and 100 pg were significantly decreased to (50\u00b795 \u00b1 4\u00b73%, P < 0\u00b70001) and (33\u00b79 \u00b1 4\u00b74%, P < 0\u00b70001) compared with PBS control (74\u00b705 \u00b1 3\u00b74%). Cytoplasm CCR1+ LN cells were significantly down\u2010regulated in mice treated with 50 pg of CCL3 (25\u00b765 \u00b1 1\u00b734%, P < 0\u00b70001) or 100 pg of CCL3 (39\u00b748 \u00b1 2\u00b74%, P < 0\u00b70001) compared with PBS\u2010treated control mice (73\u00b775 \u00b1 1\u00b74%) (Fig. 3b). A histogram of surface and cytoplasm CCR1+ PBMC after treatment with CCL3 is presented in Fig. 3(c).",
            "cite_spans": [],
            "section": "CCL3 down\u2010regulates the expression of CCR1+ cells in normal mice ::: Results",
            "ref_spans": [
                {
                    "start": 441,
                    "end": 442,
                    "mention": "3",
                    "ref_id": "FIGREF2"
                },
                {
                    "start": 541,
                    "end": 542,
                    "mention": "3",
                    "ref_id": "FIGREF2"
                }
            ]
        },
        {
            "text": "To down\u2010regulate CCR1+ cells in BD mice, CCL3 100 pg/day was administered to BD mice (n = 11) for five consecutive days. Frequencies of surface CCR1+ PBMC were significantly lower compared with PBS\u2010treated BD mice (n = 10) (4\u00b759 \u00b1 1\u00b736% versus 7\u00b706 \u00b1 1\u00b78%, P = 0\u00b7003). The frequencies of surface CCR1+ LN cells were not different after CCL3 treatment (Fig. 4a). Cytoplasm CCR1+ LN cells were down\u2010regulated significantly after CCL3 treatment compared with PBS control (38\u00b738 \u00b1 7\u00b774% versus 58\u00b704 \u00b1 22\u00b739%, P = 0\u00b701). However, CCR1+ expression was not changed in PBMC cytoplasm (Fig. 4b). Treatment with CCL3 deteriorated BD symptoms in 10 (62\u00b75%) of 16 BD mice and the disease severity score increased from 2\u00b773 \u00b1 0\u00b747 to 3\u00b72 \u00b1 1\u00b700 after 5 days of treatment. Four BD mice showed new skin ulcer and arthritis, and the remaining BD mice showed increased ulcer size.",
            "cite_spans": [],
            "section": "CCL3 down\u2010regulates the expression of CCR1+ cells and deteriorates symptoms in BD mice ::: Results",
            "ref_spans": [
                {
                    "start": 357,
                    "end": 358,
                    "mention": "4",
                    "ref_id": "FIGREF3"
                },
                {
                    "start": 583,
                    "end": 584,
                    "mention": "4",
                    "ref_id": "FIGREF3"
                }
            ]
        },
        {
            "text": "BX471 was developed as a CCR1 antagonist to treat several inflammatory diseases, including rheumatoid arthritis.12 BX471 was administered to BD mice to down\u2010regulate CCR1. BX471\u2010treated BD mice (n = 3) showed 8\u00b723 \u00b1 6\u00b717% of surface CCR1+ PBMC, 11\u00b753 \u00b1 3\u00b771% of surface CCR1+ LN cells, 54\u00b753 \u00b1 14\u00b759% of cytoplasm PBMC, and 67\u00b717 \u00b1 11\u00b749% of cytoplasm LN cells. In BD mice, BX471 did not play a role in the down\u2010regulation of CCR1+ cells (Fig. 4a,b). In normal mice, BX471\u2010treated mice showed higher frequencies of surface CCR1+ PBMC than in PBS\u2010treated normal mice (17\u00b722 \u00b1 8\u00b766% versus 12\u00b715 \u00b1 7\u00b792%, P = 0\u00b73) and LN cells (15\u00b766 \u00b1 1\u00b714% versus 13\u00b715 \u00b1 1\u00b773%, P = 0\u00b705). Inhibition of CCR1 expression by BX471 was only found in the cytoplasm of PBMC (BX471 versus PBS: 65\u00b794 \u00b1 5\u00b712% versus 74\u00b705 \u00b1 3\u00b747%, P = 0\u00b702) (Fig. 4c,d).",
            "cite_spans": [],
            "section": "BX471, a CCR1 antagonist, does not down\u2010regulate CCR1+ cells in BD mice ::: Results",
            "ref_spans": [
                {
                    "start": 444,
                    "end": 445,
                    "mention": "4",
                    "ref_id": "FIGREF3"
                },
                {
                    "start": 823,
                    "end": 824,
                    "mention": "4",
                    "ref_id": "FIGREF3"
                }
            ]
        },
        {
            "text": "Colchicine and pentoxifylline are the most frequently prescribed medications for BD.24 They are also used in BD mice.25 To determine the correlation between CCR1 expression and these two agents, colchicine (n = 7) and pentoxifylline (n = 7) were administered to 4\u2010week\u2010old normal mice. The surface expression of CCR1 in PBMC was significantly up\u2010regulated compared with PBS\u2010treated normal mice (n = 10) (colchicine versus PBS: 16\u00b702 \u00b1 2\u00b72% versus 11\u00b711 \u00b1 2\u00b739%, P = 0\u00b70006; pentoxifylline versus PBS: 17\u00b702 \u00b1 3\u00b78% versus 11\u00b711 \u00b1 2\u00b72%, P = 0\u00b7001). Colchicine significantly up\u2010regulated the expression of CCR1 on the surface of LN cells, compared with PBS\u2010treated normal mice (16\u00b702 \u00b1 2\u00b72% versus 12\u00b799 \u00b1 1\u00b756%, P = 0\u00b7005). Pentoxifylline also up\u2010regulated the expression of CCR1 compared with PBS\u2010treated normal mice, although the up\u2010regulation was not statistically significant (14\u00b78 \u00b1 3\u00b76% versus 12\u00b799 \u00b1 1\u00b756%, P = 0\u00b718) (Fig. 5a). Colchicine and pentoxifylline significantly down\u2010regulated the expression of cytoplasm CCR1+ PBMC (59\u00b737 \u00b1 11\u00b75%, P = 0\u00b7002; 59\u00b77 \u00b1 18\u00b78%, P = 0\u00b703, respectively) compared with PBS control (73\u00b765 \u00b1 3\u00b70%). Cytoplasm CCR1 expression in LN cells was not altered under colchicine or pentoxifylline treatment (Fig. 5b).",
            "cite_spans": [],
            "section": "Drug treatment regulates frequencies of CCR1+ cells in normal mice ::: Results",
            "ref_spans": [
                {
                    "start": 929,
                    "end": 930,
                    "mention": "5",
                    "ref_id": "FIGREF4"
                },
                {
                    "start": 1244,
                    "end": 1245,
                    "mention": "5",
                    "ref_id": "FIGREF4"
                }
            ]
        },
        {
            "text": "Frequencies of CCR1+ cells were determined after BD mice were treated with medication. Treatment with colchicine (n = 7) or pentoxifylline (n = 7) significantly up\u2010regulated CCR1 surface expression in PBMC of BD mice compared with PBS\u2010treated BD mice (n = 10) (15\u00b792 \u00b1 4\u00b75% versus 7\u00b706 \u00b1 1\u00b78%, P < 0\u00b70001; 19\u00b7083 \u00b1 3\u00b74% versus 7\u00b706 \u00b1 1\u00b78%, P < 0\u00b70001, respectively). The frequencies of surface CCR1+ LN cells were also increased significantly by colchicine or pentoxifylline compared with the PBS\u2010treated BD mice (17\u00b768 \u00b1 7\u00b79% versus 10\u00b76 \u00b1 3\u00b723%, P = 0\u00b702; 21\u00b736 \u00b1 4% versus 10\u00b76 \u00b1 6\u00b79%, P < 0\u00b70001, respectively) (Fig. 5c). In the cytoplasm of PBMC, treatment with colchicine and pentoxifylline increased the frequencies of CCR1+ cells. However, only pentoxifylline treatment resulted in a significant increase (77\u00b74 \u00b1 6\u00b797% versus 32\u00b708 \u00b1 16\u00b739%, P < 0\u00b70001), colchicine or pentoxifylline did not affect the frequency of cytoplasm CCR1+ LN cells compared with PBS\u2010treated BD mice (Fig. 5d). The histogram of CCR1+ expression in the surface and cytoplasm of PBMC after treatment with colchicine and pentoxifylline is presented in Fig. 5(e). Results show that the frequencies of surface CCR1+ expression rather than cytoplasm expression strongly correlated with the regulation of BD symptoms.",
            "cite_spans": [],
            "section": "Drug treatment regulates frequencies of CCR1+ cells in BD mice ::: Results",
            "ref_spans": [
                {
                    "start": 621,
                    "end": 622,
                    "mention": "5",
                    "ref_id": "FIGREF4"
                },
                {
                    "start": 989,
                    "end": 990,
                    "mention": "5",
                    "ref_id": "FIGREF4"
                },
                {
                    "start": 1137,
                    "end": 1138,
                    "mention": "5",
                    "ref_id": "FIGREF4"
                }
            ]
        },
        {
            "text": "To determine whether CCR1 was regulated by CCL3 inhibition, anti\u2010CCL3 antibody was intraperitoneally injected into normal mice. Frequencies of CCR1+ PBMC and LN cells were increased after anti\u2010CCL3 antibody treatment. In surface staining of PBMC, treatment with anti\u2010CCL3 antibody at 1\u2013200 ng significantly increased frequencies of CCR1+ cells compared with PBS\u2010treated normal mice (1 ng, 12\u00b784 \u00b1 1\u00b798%, P = 0\u00b7009; 2 ng, 13\u00b737 \u00b1 2\u00b728%, P = 0\u00b7002; 20 ng, 15\u00b728 \u00b1 2\u00b757%, P < 0\u00b70001; 50 ng, 16\u00b792 \u00b1 1\u00b732%, P < 0\u00b70001; 200 ng, 15\u00b76 \u00b1 2\u00b712%, P = 0\u00b70005; versus PBS, 8\u00b73 \u00b1 2\u00b704%). In surface staining of LN cells, treatment with anti\u2010CCL3 antibody significantly up\u2010regulated frequencies of CCR1+ LN cells compared with PBS\u2010treated normal mice (1 ng, 15\u00b716 \u00b1 2\u00b783%, P < 0\u00b70001; 2 ng, 17\u00b762 \u00b1 4\u00b724%, P < 0\u00b70001; 20 ng, 19\u00b74 \u00b1 1\u00b759%, P < 0\u00b70001; 50 ng, 19\u00b782 \u00b1 1\u00b776%, P < 0\u00b70001; 200 ng, 16\u00b775 \u00b1 5\u00b758%, P = 0\u00b70008; versus PBS, 8\u00b772 \u00b1 1\u00b721%) (Fig. 6a). In the cytoplasm, frequencies of CCR1+ PBMC after treatment with anti\u2010CCL3 antibody at 1\u2013200 ng were not altered significantly in PBMC cytoplasm compared with PBS\u2010treated normal mice (1 ng, 64\u00b736 \u00b1 11\u00b782%; 2 ng, 55\u00b775 \u00b1 3\u00b733%; 20 ng, 53\u00b794 \u00b1 5\u00b704%; 50 ng, 64\u00b765 \u00b1 8\u00b783%; 200 ng, 40\u00b705 \u00b1 2\u00b733%; versus PBS, 52\u00b745 \u00b1 13\u00b742%) (Fig. 6b). Cytoplasm CCR1+ LN cells were significantly up\u2010regulated in mice treated with 1 ng of anti\u2010CCL3 antibody (42\u00b712 \u00b1 8\u00b793%, P = 0\u00b702) or 200 ng of anti\u2010CCL3 antibody (59\u00b70 \u00b1 7\u00b777%, P = 0\u00b70002) compared with PBS\u2010treated normal mice (30\u00b70 \u00b1 7\u00b727%). Treatment with 2, 20 and 50 ng of anti\u2010CCL3 did not yield significant changes compared with PBS\u2010treated normal mice (Fig. 6b).",
            "cite_spans": [],
            "section": "Anti\u2010CCL3 antibody up\u2010regulates the expression of CCR1+ cells and improves symptoms in BD mice ::: Results",
            "ref_spans": [
                {
                    "start": 938,
                    "end": 939,
                    "mention": "6",
                    "ref_id": "FIGREF5"
                },
                {
                    "start": 1271,
                    "end": 1272,
                    "mention": "6",
                    "ref_id": "FIGREF5"
                },
                {
                    "start": 1642,
                    "end": 1643,
                    "mention": "6",
                    "ref_id": "FIGREF5"
                }
            ]
        },
        {
            "text": "To up\u2010regulate CCR1+ cells in BD mice, anti\u2010CCL3 antibody 20 ng/day was administered to BD mice (n = 16) for five consecutive days. The frequencies of CCR1+ expression on the surface of PBMC were significantly increased compared with those in PBS\u2010treated BD mice (n = 10) (15\u00b761 \u00b1 2\u00b792% versus 7\u00b792 \u00b1 2\u00b761%, P < 0\u00b70001). In LN cells, frequencies of surface CCR1+ expressions were significantly increased after anti\u2010CCL3 antibody treatment (22\u00b78 \u00b1 2\u00b77% versus 10\u00b76 \u00b1 3\u00b71%, P = 0\u00b70001) (Fig. 7a). In the cytoplasm of PBMC, the frequencies of CCR1 expression after treatment with anti\u2010CCL3 antibody were up\u2010regulated significantly compared with PBS control (51\u00b742 \u00b1 13\u00b708% versus 32\u00b711 \u00b1 16\u00b740%, P < 0\u00b70001). However, the cytoplasm CCR1+ LN cells were down\u2010regulated after treatment with anti\u2010CCL3 antibody compared with PBS control (40\u00b762 \u00b1 7\u00b781% versus 58\u00b704 \u00b1 22\u00b743%, P = 0\u00b7008; Fig. 7b). Anti\u2010CCL3 antibody treatment improved BD symptoms in 10 (50\u00b70%) of 20 BD mice on day 5 after initiation with anti\u2010CCL3 antibody treatment. The list of improved mice is provided in the Supplementary material (Table S1). The disease severity score in BD mice changed from 3\u00b71 \u00b1 0\u00b73 to 2\u00b745 \u00b1 0\u00b768 on day 5 with symptom improvement after anti\u2010CCL3 antibody treatment (P < 0\u00b70001). Disease severity score was also significantly varied between CCL3\u2010treated BD mice (3\u00b72 \u00b1 1\u00b70) and anti\u2010CCL3 antibody\u2010treated BD mice (2\u00b745 \u00b1 0\u00b768) on day five (P = 0\u00b7004) (Fig. 7c). Figure 7(d) show the changes in symptoms after treatment with CCL3 or anti\u2010CCL3 antibody in BD mice.",
            "cite_spans": [],
            "section": "Anti\u2010CCL3 antibody up\u2010regulates the expression of CCR1+ cells and improves symptoms in BD mice ::: Results",
            "ref_spans": [
                {
                    "start": 490,
                    "end": 491,
                    "mention": "7",
                    "ref_id": "FIGREF6"
                },
                {
                    "start": 884,
                    "end": 885,
                    "mention": "7",
                    "ref_id": "FIGREF6"
                },
                {
                    "start": 1444,
                    "end": 1445,
                    "mention": "7",
                    "ref_id": "FIGREF6"
                },
                {
                    "start": 1456,
                    "end": 1457,
                    "mention": "7",
                    "ref_id": "FIGREF6"
                }
            ]
        },
        {
            "text": "The levels of CCL3 in patients with active BD (76\u00b788 \u00b1 74\u00b748 pg/ml) were higher than in patients with inactive BD (24\u00b758 \u00b1 7\u00b754 pg/ml, P = 0\u00b709) and healthy control individuals (22\u00b782 \u00b1 7\u00b787 pg/ml, P = 0\u00b702) (Fig. 8).",
            "cite_spans": [],
            "section": "Plasma levels of CCL3 in patients with BD ::: Results",
            "ref_spans": [
                {
                    "start": 214,
                    "end": 215,
                    "mention": "8",
                    "ref_id": "FIGREF7"
                }
            ]
        },
        {
            "text": "This study quantitatively analyzed the expression of chemokine receptors in PBMC and LN cells of BD mice. Our results suggest that BD\u2010like symptoms were correlated with frequencies of CCR1+ cells. Percentages of CCR1+ cells were significantly down\u2010regulated in BD mice compared with normal or BDN mice. Cytokine IL\u201010\u2010 and GM\u2010CSF\u2010treated BD mice exhibited significant up\u2010regulation of CCR1+ cells compared with PBS\u2010treated BD mice. CCR1 ligand CCL3\u2010treated BD mice showed significant down\u2010regulation of CCR1+ cells compared with PBS\u2010treated BD mice. Ten of 16 CCL3\u2010treated BD mice showed deteriorated BD symptoms. Anti\u2010CCL3 antibody treatment improved BD symptoms, decreased the disease severity score, and up\u2010regulated CCR1+ cells significantly compared with PBS\u2010treated BD mice. Treatment of BD mice with colchicine and pentoxifylline significantly up\u2010regulated CCR1+ cells compared with PBS treatment. Frequencies of CCR1+ cells were strongly associated with symptoms in BD mice.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "Chemokine receptors are essential moderators of leukocyte trafficking in inflammatory diseases. CCR1 may be a strong therapeutic target in a variety of diseases.26 CCR1 has been shown to play a role in recruiting monocytes and Th1 cells according to active inflammation.27 CCR1 and its ligands are associated with the development of experimental arthritis. In rheumatoid arthritis, CCR1 is an efficient therapeutic target because it mediates the regulation of tumor necrosis factor\u2010\u03b1 and IL\u201010.28 However, in patients with BD, the frequencies of CCR1+ cells are decreased in patients with active BD than in normal controls, even though the difference was not statistically significant.29 Similarly, this study also shows that the frequencies of CCR1+ cells in BD mice were down\u2010regulated compared with the control mice. Down\u2010regulated CCR1 expression has been reported after infection with Leishmania infantum\n30 or coronavirus.31 Correlation between HSV infection and CCR1 expression does not show consistent results.32, 33\n",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "Chemokine CCL3 expression has been reported in arthritic inflammation.34 CCL3 recruits inflammatory leukocytes by binding to CCR1.35 It affects chronic joint inflammation.36 Neutralizing antibodies to CCL3 alleviate inflammation.37 Higher serum levels of CCL3 have been found in patients with active BD than in patients with inactive stages of BD.38 Results of the present study demonstrate that treatment with CCL3 deteriorated symptoms in BD mice and down\u2010regulated the frequencies of CCR1+ cells. Increased CCL3 expression exacerbates BD symptoms through down\u2010regulation of CCR1.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "Interleukin\u201010 is known as a CCR1 stimulator.39 It is mainly expressed in monocytes, macrophages, Th2 cells, and B cells. IL\u201010 is one of the key anti\u2010inflammatory cytokines expressed in the human immune response. It is a strong inhibitor of Th1 cytokines IL\u20102 and interferon\u2010\u03b3.40, 41 Anti\u2010inflammatory cytokine IL\u201010 suppresses pro\u2010inflammatory cytokines and protects the host against tissue damage.42 In patients with BD, IL\u201010 polymorphisms have been identified.43, 44 Such gene variation might be correlated with insufficient expression of IL\u201010. Results of the present study show that IL\u201010 up\u2010regulated the frequencies of CCR1+ cells in BD mice compared with PBS control. IL\u201010 and GM\u2010CSF also synergistically increased the frequencies of CCR1+ cells in BD mice.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "Granulocyte\u2013macrophage colony\u2010stimulating factor is a stimulator of CCR1 expression.22 It enhances the maturation of dendritic cells and plays a role in recruiting circulating neutrophils, monocytes and lymphocytes for host defense.45 Different types of inflammatory and immune cells such as dendritic cells, monocytes, neutrophils, microglia and macrophages are modulated by GM\u2010CSF under autoimmune conditions.46 GM\u2010CSF may influence chronic inflammatory diseases such as arthritis,47 experimental autoimmune encephalitis48 and airway inflammation.49 GM\u2010CSF also enhances resistance to viral infection50 and bacterial translocation.51 In patients with BD, GM\u2010CSF transcription was down\u2010regulated more than in controls.52 However, the protein expression or serum levels of GM\u2010CSF in patients with BD have yet to be elucidated. According to a case report, intra\u2010lesional injection with recombinant human GM\u2010CSF induces wound healing in genital ulcers of BD.53 GM\u2010CSF also enhances CCR1 expression.21, 22 Our data demonstrated that treatment with GM\u2010CSF significantly up\u2010regulated CCR1+ expression in PBMC and LN cells.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "BX471 was developed as a potent antagonist against CCR1.54 BX471 treatment attenuated systemic inflammation of sepsis,55 nephritis,56 arthritis57 and myocarditis.58 In our study, BX471 was administered to BD mice to confirm the correlation of CCR1 expression with BD by inhibiting CCR1. BX471 treatment failed to inhibit the frequencies of surface or cytoplasm CCR1+ PBMC and LN cells in BD mice. In normal mice, BX471 inhibited the expression of CCR1 only in the cytoplasm of PBMC. These results indicate that BX471 treatment failed to adequately inhibit CCR1+ cells in vivo, which partly explains why clinical trials of BX471 inhibition of CCR1 were discontinued.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "In conclusion, our study demonstrated down\u2010regulated frequencies of CCR1+ cells, which were closely correlated with BD symptoms and the expression of CCR1+ cells was controlled by cytokine IL\u201010, GM\u2010CSF and ligand CCL3. Even though BD is a multi\u2010factorial inflammatory disease associated with immune dysregulation, treatment with single chemokine or chemokine receptor alone contributes to immune regulation resulting in the control of systemic symptoms of BD.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "The authors declare no conflicts of interest.",
            "cite_spans": [],
            "section": "Disclosure",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Clinical characteristics of patients with Beh\u00e7et's disease\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: Therapeutic history of patients with Beh\u00e7et's disease\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: Frequencies of CCR1+ cells in normal, herpes simplex virus\u2010inoculated, but asymptomatic healthy (BDN) and Beh\u00e7et's disease (BD) mice. Peripheral blood mononuclear cells (PBMC) and lymph node cells were isolated from normal, BDN and BD mice. Frequencies of surface CCR1+ cells (a) and cytoplasm CCR1+ cells (b) of whole leukocytes were analyzed by FACS. Representative flow cytometric histograms of surface CCR1+ PBMC and lymph node cells are shown (c). (d) Protein expression of CCR1 by Western blot, (e) Expression ratio of CCR1 to GAPDH.",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Figure 2: Frequencies of CCR1+ cells in cytokine\u2010treated normal and Beh\u00e7et's disease (BD) mice. Interleukin\u201010 (IL\u201010) (25, 50 and 100 pg) and granulocyte\u2013macrophage colony\u2010stimulating factor (GM\u2010CSF) (50, 100 and 200 pg) were intraperitoneally injected into normal mice for five consecutive days and peripheral blood mononuclear cells (PBMC) were isolated. Frequencies of CCR1+ cells were analyzed by FACS for expression on the surface and in the cytoplasm of mice after treatment with IL\u201010 (a) or GM\u2010CSF (b). IL\u201010 (50 pg) and GM\u2010CSF (200 pg) were intraperitoneally injected into BD mice for five consecutive days. PBMC and lymph node cells were isolated. Frequencies of surface CCR1+ (c) and cytoplasm CCR1+ (d) PBMC and lymph node cells derived from IL\u201010\u2010 and GM\u2010CSF\u2010treated BD mice were analyzed by FACS.",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Figure 3: Frequencies of CCR1+ cells in CCL3\u2010treated normal mice. CCL3 (50 pg and 100 pg) was intraperitoneally injected into normal mice for five consecutive days. Peripheral blood mononuclear cells (PBMC) and lymph node cells were then isolated. Frequencies of CCR1+ cells were analyzed by FACS on the surface (a) and in the cytoplasm (b) of PBMC and lymph node cells. Representative flow cytometric histograms of CCR1+ cells on the surface (a) and in the cytoplasm (b) of PBMC are shown in (c).",
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Figure 4: Frequencies of CCR1+ cells in CCL3\u2010 and BX471\u2010treated Beh\u00e7et's disease (BD) mice. CCL3 and BX471 were used to treat BD mice and frequencies of CCR1+ cells were analyzed by FACS on the surface (a) and in the cytoplasm (b) of peripheral blood mononuclear cells (PBMC) and lymph node cells. Frequencies of CCR1+ cells in normal mice after treatment with BX471 are shown in (c) and (d).",
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Figure 5: Frequencies of CCR1+ cells in colchicine (Col) and pentoxifylline (Pento) \u2010treated normal and Beh\u00e7et's disease (BD) mice. Colchicine (2 \u03bcg/mouse/day) and pentoxifylline (400 \u03bcg/mouse/day) were used to treat mice. Frequencies of surface and cytoplasm CCR1+ peripheral blood mononuclear cells (PBMC) and lymph node cells were analyzed in normal mice (a, b) and BD mice (c, d) by FACS. (e) Representative flow cytometric histogram of surface and cytoplasm CCR1+ PBMC following colchicine or pentoxifylline treatment of BD mice.",
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Figure 6: Frequencies of CCR1+ cells in anti\u2010CCL3 antibody\u2010treated normal mice. Anti\u2010CCL3 antibody (1, 2, 20, 50 and 200 ng) was intraperitoneally injected into normal mice for five consecutive days. Peripheral blood mononuclear cells (PBMC) and lymph node cells were isolated. Frequencies of surface CCR1+ (a) and cytoplasm CCR1+ (b) PBMC and lymph node cells were analyzed by FACS.",
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Figure 7: Frequencies of CCR1+ cells in anti\u2010CCL3 antibody\u2010treated Beh\u00e7et's disease (BD) mice. Anti\u2010CCL3 antibody 20 ng was intraperitoneally injected into BD mice for five consecutive days. Peripheral blood mononuclear cells (PBMC) and lymph node cells were then isolated. Frequencies of surface CCR1+ (a) and cytoplasm CCR1+ (b) PBMC and lymph node cells were analyzed by FACS. (c) The changes in disease severity score after CCL3 or anti\u2010CCL3 antibody treatment of BD mice. (d) Symptoms of BD mice after CCL3 or anti\u2010CCL3 antibody treatment.",
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Figure 8: Plasma levels of CCL3 in patients with active and inactive Beh\u00e7et's disease (BD).",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Two\u2010stage association study in Chinese Han identifies two independent associations in CCR1/CCR1 locus as candidate for Beh\u00e7et's disease susceptibility",
            "authors": [],
            "year": 2012,
            "venue": "Hum Genet",
            "volume": "131",
            "issn": "",
            "pages": "1841-50",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Genome\u2010wide association analysis identifies new susceptibility loci for Beh\u00e7et's disease and epistasis between HLA\u2010B*51 and ERAP1",
            "authors": [],
            "year": 2013,
            "venue": "Nat Genet",
            "volume": "45",
            "issn": "",
            "pages": "202-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Preparation of specific polyclonal antibodies to a C\u2010C chemokine receptor, CCR3, and determination of CCR3 expression on various types of leukocytes",
            "authors": [],
            "year": 1996,
            "venue": "J Leukoc Biol",
            "volume": "60",
            "issn": "",
            "pages": "658-66",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Human lung dendritic cells have an immature phenotype with efficient mannose receptors",
            "authors": [],
            "year": 1999,
            "venue": "Am J Respir Cell Mol Biol",
            "volume": "21",
            "issn": "",
            "pages": "547-54",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Impaired host defense, hematopoiesis, granulomatous inflammation and type 1\u2010type 2 cytokine balance in mice lacking CC chemokine receptor 1",
            "authors": [],
            "year": 1997,
            "venue": "J Exp Med",
            "volume": "185",
            "issn": "",
            "pages": "1959-68",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Up\u2010regulation of CCR6 and CCR6 and induction of chemotaxis to CC chemokines by IFN\u2010\u03b3 in human neutrophils",
            "authors": [],
            "year": 1999,
            "venue": "J Immunol",
            "volume": "162",
            "issn": "",
            "pages": "474-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis",
            "authors": [],
            "year": 2001,
            "venue": "Arthritis Rheum",
            "volume": "44",
            "issn": "",
            "pages": "1022-32",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Expression and regulation of CCR8 by airway smooth muscle cells in asthma",
            "authors": [],
            "year": 2008,
            "venue": "J Immunol",
            "volume": "180",
            "issn": "",
            "pages": "1268-75",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "CCR9 inhibition ameliorates the progression of lupus nephritis in NZB/W mice",
            "authors": [],
            "year": 2014,
            "venue": "J Immunol",
            "volume": "192",
            "issn": "",
            "pages": "886-96",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Airway remodeling is absent in CCR10\u2013/\u2013 mice during chronic fungal allergic airway disease",
            "authors": [],
            "year": 2000,
            "venue": "J Immunol",
            "volume": "165",
            "issn": "",
            "pages": "1564-72",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "CCR11/CCL5 (RANTES) receptor\u2013ligand interactions modulate allogeneic T\u2010cell responses and graft\u2010versus\u2010host disease following stem\u2010cell transplantation",
            "authors": [],
            "year": 2007,
            "venue": "Blood",
            "volume": "110",
            "issn": "",
            "pages": "3447-55",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Chemokine receptor antagonists: overcoming developmental hurdles",
            "authors": [],
            "year": 2009,
            "venue": "Nat Rev Drug Discov",
            "volume": "8",
            "issn": "",
            "pages": "23-33",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Detection of RNA complementary to herpes\u2010simplex virus in mononuclear cells from patients with Beh\u00e7et's syndrome and recurrent oral ulcers",
            "authors": [],
            "year": 1982,
            "venue": "Lancet",
            "volume": "2",
            "issn": "",
            "pages": "1356-61",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "CD4 and CD8 cell responses to herpes simplex virus in Beh\u00e7et's disease",
            "authors": [],
            "year": 1988,
            "venue": "Clin Exp Immunol",
            "volume": "73",
            "issn": "",
            "pages": "6-10",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "\u00dcber rezidivierende, aphth\u00f6se, durch ein virus verursachte geschw\u00fcre am mund, am auge und an den genitalien",
            "authors": [],
            "year": 1937,
            "venue": "Dermatologische Wochenschrift",
            "volume": "105",
            "issn": "",
            "pages": "1152-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Beh\u00e7et's disease\u2010like symptoms induced by the Herpes simplex virus in ICR mice",
            "authors": [],
            "year": 1998,
            "venue": "Eur J Dermatol",
            "volume": "8",
            "issn": "",
            "pages": "21-3",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Learning from HSV\u2010infected mice as a model of Beh\u00e7et's disease",
            "authors": [],
            "year": 2012,
            "venue": "Clin Exp Rheumatol",
            "volume": "30",
            "issn": "",
            "pages": "S96-103",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Immunopathogenic role of herpes simplex virus in Beh\u00e7et's disease",
            "authors": [],
            "year": 2013,
            "venue": "Genet Res Int",
            "volume": "2013",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Serum reactivity against herpes simplex virus type 1 UL48 protein in Beh\u00e7et's disease patients and a Beh\u00e7et's disease\u2010like mouse model",
            "authors": [],
            "year": 2015,
            "venue": "Acta Derm Venereol",
            "volume": "95",
            "issn": "",
            "pages": "952-8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "The spectrum of mucocutaneous manifestations in Adamantiades\u2010Beh\u00e7et's disease in Greece",
            "authors": [],
            "year": 2010,
            "venue": "J Eur Acad Dermatol Venereol",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "IL\u201010 synergistically enhances GM\u2010CSF\u2010induced CCR21 expression in myelomonocytic cells",
            "authors": [],
            "year": 2003,
            "venue": "Biochem Biophys Res Commun",
            "volume": "304",
            "issn": "",
            "pages": "417-24",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Granulocyte\u2013macrophage colony stimulating factor up\u2010regulates CCR22 in human neutrophils",
            "authors": [],
            "year": 2001,
            "venue": "J Immunol",
            "volume": "166",
            "issn": "",
            "pages": "1178-84",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Differential pattern of CCR23 internalization in human eosinophils: prolonged internalization by CCL5 in contrast to CCL3",
            "authors": [],
            "year": 2005,
            "venue": "Allergy",
            "volume": "60",
            "issn": "",
            "pages": "1386-93",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Treatment of Beh\u00e7et's disease",
            "authors": [],
            "year": 1997,
            "venue": "Yonsei Med J",
            "volume": "38",
            "issn": "",
            "pages": "401-10",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "The relevance of miRNA\u201021 in HSV\u2010induced inflammation in a mouse model",
            "authors": [],
            "year": 2015,
            "venue": "Int J Mol Sci",
            "volume": "16",
            "issn": "",
            "pages": "7413-27",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Chemokines and disease",
            "authors": [],
            "year": 2001,
            "venue": "Nat Immunol",
            "volume": "2",
            "issn": "",
            "pages": "108-15",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "The role of chemokines in the recruitment of lymphocytes to the liver",
            "authors": [],
            "year": 2010,
            "venue": "Dig Dis",
            "volume": "28",
            "issn": "",
            "pages": "31-44",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "Pharmacological blockade of CCR28 ameliorates murine arthritis and alters cytokine networks in vivo\n",
            "authors": [],
            "year": 2006,
            "venue": "Br J Pharmacol",
            "volume": "149",
            "issn": "",
            "pages": "666-75",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Abnormal expression of chemokine receptors in Beh\u00e7et's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations",
            "authors": [],
            "year": 2004,
            "venue": "J Autoimmun",
            "volume": "23",
            "issn": "",
            "pages": "267-73",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "Reduced expression of the chemokine receptor CCR30 in human macrophages and U\u2010937 cells in vitro infected with Leishmania infantum\n",
            "authors": [],
            "year": 2004,
            "venue": "Clin Exp Med",
            "volume": "3",
            "issn": "",
            "pages": "225-30",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "CCR31 deficiency increases susceptibility to fatal coronavirus infection of the central nervous system",
            "authors": [],
            "year": 2007,
            "venue": "Viral Immunol",
            "volume": "20",
            "issn": "",
            "pages": "599-608",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "Persistent expression of chemokine and chemokine receptor RNAs at primary and latent sites of herpes simplex virus 1 infection",
            "authors": [],
            "year": 2004,
            "venue": "Virol J",
            "volume": "1",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "Blocking CC chemokine receptor (CCR) 1 and CCR33 during herpes simplex virus type 2 infection in vivo impairs host defence and perturbs the cytokine response",
            "authors": [],
            "year": 2004,
            "venue": "Scand J Immunol",
            "volume": "59",
            "issn": "",
            "pages": "321-33",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF33": {
            "title": "Genome\u2010wide haplotype association analysis and gene prioritization identify CCL3 as a risk locus for rheumatoid arthritis",
            "authors": [],
            "year": 2010,
            "venue": "Int J Immunogenet",
            "volume": "37",
            "issn": "",
            "pages": "273-8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF34": {
            "title": "Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease",
            "authors": [],
            "year": 2014,
            "venue": "Biochim Biophys Acta",
            "volume": "1843",
            "issn": "",
            "pages": "2563-82",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF35": {
            "title": "An essential role for CCL3 in the development of collagen antibody\u2010induced arthritis",
            "authors": [],
            "year": 2005,
            "venue": "Immunol Lett",
            "volume": "100",
            "issn": "",
            "pages": "202-4",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF36": {
            "title": "Crucial role of CCL3/MIP\u20101\u03b1 in the recurrence of autoimmune anterior uveitis induced with myelin basic protein in Lewis rats",
            "authors": [],
            "year": 2002,
            "venue": "J Autoimmun",
            "volume": "18",
            "issn": "",
            "pages": "259-70",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF37": {
            "title": "Enhanced production of macrophage inhibitory protein\u20101\u03b1 in patients with Beh\u00e7et's disease",
            "authors": [],
            "year": 2005,
            "venue": "Scand J Rheumatol",
            "volume": "34",
            "issn": "",
            "pages": "129-35",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF38": {
            "title": "IL\u201010 enhances CCL2 release and chemotaxis induced by CCL16 in human monocytes",
            "authors": [],
            "year": 2005,
            "venue": "Int J Immunopathol Pharmacol",
            "volume": "18",
            "issn": "",
            "pages": "339-49",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF39": {
            "title": "IL\u201010 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell\u2010induced delayed\u2010type hypersensitivity",
            "authors": [],
            "year": 1994,
            "venue": "J Immunol",
            "volume": "153",
            "issn": "",
            "pages": "3967-78",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF40": {
            "title": "The regulation of IL\u201010 production by immune cells",
            "authors": [],
            "year": 2010,
            "venue": "Nat Rev Immunol",
            "volume": "10",
            "issn": "",
            "pages": "170-81",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF41": {
            "title": "Interleukin\u201010 and immunity against prokaryotic and eukaryotic intracellular pathogens",
            "authors": [],
            "year": 2011,
            "venue": "Infect Immun",
            "volume": "79",
            "issn": "",
            "pages": "2964-73",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF42": {
            "title": "Genome\u2010wide association studies identify IL23R\u2010IL12RB2 and IL10 as Beh\u00e7et's disease susceptibility loci",
            "authors": [],
            "year": 2010,
            "venue": "Nat Genet",
            "volume": "42",
            "issn": "",
            "pages": "703-6",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF43": {
            "title": "Genome\u2010wide association study identifies variants in the MHC class I, IL10, and IL23R\u2010IL12RB2 regions associated with Beh\u00e7et's disease",
            "authors": [],
            "year": 2010,
            "venue": "Nat Genet",
            "volume": "42",
            "issn": "",
            "pages": "698-702",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF44": {
            "title": "Granulocyte\u2013macrophage colony\u2010stimulating factor (GM\u2010CSF) and T\u2010cell responses: what we do and don't know",
            "authors": [],
            "year": 2006,
            "venue": "Cell Res",
            "volume": "16",
            "issn": "",
            "pages": "126-33",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF45": {
            "title": "GM\u2010CSF: an immune modulatory cytokine that can suppress autoimmunity",
            "authors": [],
            "year": 2015,
            "venue": "Cytokine",
            "volume": "75",
            "issn": "",
            "pages": "261-71",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF46": {
            "title": "G\u2010CSF and GM\u2010CSF as therapeutic targets in rheumatoid arthritis",
            "authors": [],
            "year": 2009,
            "venue": "Nat Rev Rheumatol",
            "volume": "5",
            "issn": "",
            "pages": "554-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF47": {
            "title": "GM\u2010CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis",
            "authors": [],
            "year": 2007,
            "venue": "J Immunol",
            "volume": "178",
            "issn": "",
            "pages": "39-48",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF48": {
            "title": "Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM\u2010CSF\u2010mediated mechanism",
            "authors": [],
            "year": 2004,
            "venue": "J Immunol",
            "volume": "173",
            "issn": "",
            "pages": "6384-92",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF49": {
            "title": "GM\u2010CSF in the lung protects against lethal influenza infection",
            "authors": [],
            "year": 2011,
            "venue": "Am J Respir Crit Care Med",
            "volume": "184",
            "issn": "",
            "pages": "259-68",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF50": {
            "title": "Effect of granulocyte\u2013macrophage colony stimulating factor on bacterial translocation after experimental obstructive jaundice",
            "authors": [],
            "year": 2001,
            "venue": "Eur J Surg",
            "volume": "167",
            "issn": "",
            "pages": "366-70",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF51": {
            "title": "Granulocyte colony\u2010stimulating factor (G\u2010CSF) and granulocyte\u2013macrophage colony\u2010stimulating factor (GM\u2010CSF) in Beh\u00e7et's disease",
            "authors": [],
            "year": 1994,
            "venue": "J Dermatol",
            "volume": "21",
            "issn": "",
            "pages": "546-52",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF52": {
            "title": "Local intralesional therapy with rhGM\u2010CSF for a large genital ulcer in Beh\u00e7et's disease",
            "authors": [],
            "year": 1997,
            "venue": "Br J Dermatol",
            "volume": "136",
            "issn": "",
            "pages": "639-40",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF53": {
            "title": "Predictions of CCR54 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation",
            "authors": [],
            "year": 2006,
            "venue": "J Biol Chem",
            "volume": "281",
            "issn": "",
            "pages": "27613-20",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF54": {
            "title": "Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis",
            "authors": [],
            "year": 2007,
            "venue": "Am J Physiol Gastrointest Liver Physiol",
            "volume": "292",
            "issn": "",
            "pages": "G1173-80",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF55": {
            "title": "Late onset of treatment with a chemokine receptor CCR56 antagonist prevents progression of lupus nephritis in MRL\u2010Fas(lpr) mice",
            "authors": [],
            "year": 2004,
            "venue": "J Am Soc Nephrol",
            "volume": "15",
            "issn": "",
            "pages": "1504-13",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF56": {
            "title": "Why CCR57 and CCR57 blockade failed and why CCR57 blockade might still be effective in the treatment of rheumatoid arthritis",
            "authors": [],
            "year": 2011,
            "venue": "PLoS ONE",
            "volume": "6",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF57": {
            "title": "A CCR58 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation",
            "authors": [],
            "year": 2006,
            "venue": "J Mol Cell Cardiol",
            "volume": "40",
            "issn": "",
            "pages": "853-61",
            "other_ids": {
                "DOI": []
            }
        }
    }
}